<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1028-9933</journal-id>
<journal-title><![CDATA[Revista Información Científica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. inf. cient.]]></abbrev-journal-title>
<issn>1028-9933</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas Guantánamo]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1028-99332019000300413</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Implicaciones diagnósticas, terapéuticas y pronósticas de la mutación BRAF V600E en melanomas cutáneos]]></article-title>
<article-title xml:lang="en"><![CDATA[Diagnostic, therapeutic and prognostic implications of the BRAF V600E mutation in cutaneous melanomas]]></article-title>
<article-title xml:lang="pt"><![CDATA[Implicações diagnósticas, terapêuticas e prognósticas da mutação BRAF V600E em melanomas cutâneos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Piamo Morales]]></surname>
<given-names><![CDATA[Alberto José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Clínico Quirúrgico Docente &#8220;Joaquín Albarrán&#8221;.  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>98</volume>
<numero>3</numero>
<fpage>413</fpage>
<lpage>424</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1028-99332019000300413&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1028-99332019000300413&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1028-99332019000300413&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: el melanoma representa el 4 % de todos los tumores malignos de la piel, pero es responsable del 80 % de las muertes por cáncer en este sitio. El surgimiento de las terapias dirigidas contra la mutación de BRAF ha cambiado el pronóstico, de allí, la importancia de identificar esta mutación en los pacientes con diagnóstico histológico de melanoma maligno ya que la tasa de mutaciones del oncogén BRAF es alta.  Objetivo: describir las implicaciones diagnósticas, terapéuticas y pronósticas de la determinación de la mutación del gen BRAF V600E en el melanoma maligno cutáneo.  Método: revisión bibliográfica vía PUBMED con la introducción de los siguientes términos de búsqueda: melanoma, melanoma AND genetics, melanoma AND BRAF mutation, melanoma AND BRAF V600E AND prognosis. Se identificaron 72 publicaciones.  Resultados:  múltiples estudios han corroborado la alta frecuencia del oncogén BRAF V600E mutado en el melanoma cutáneo, ofreciendo la posibilidad de que a través de la identificación de dicha alteración se pueda contribuir a mejorar el diagnóstico y a garantizar un tratamiento dirigido específicamente contra la actividad de BRAF.  Conclusiones: la identificación de la mutación del oncogén BRAF representa un factor pronóstico y puede representar una diana terapéutica eficaz.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Melanoma accounts for 4% of all malignant skin tumors, but is responsible for 80% of cancer deaths in this site. The emergence of therapies directed against the BRAF mutation has changed the prognosis, hence the importance of identifying this mutation in patients with histological diagnosis of malignant melanoma since the rate of mutations of the BRAF oncogene is high.  Objective:  to describe the diagnostic, therapeutic and prognostic implications of the determination of the mutation of the BRAF V600E gene in cutaneous malignant melanoma.  Method:  literature review via PUBMED with the introduction of the following search terms: melanoma, melanoma AND genetics, melanoma AND BRAF mutation, melanoma AND BRAF V600E AND prognosis. 72 publications were identified.  Results:  multiple studies have corroborated the high frequency of the mutated BRAF V600E oncogene in cutaneous melanoma, offering the possibility that through the identification of this alteration it can contribute to improve the diagnosis and to guarantee a treatment directed specifically against the activity of BRAF.  Conclusions:  the identification of the BRAF oncogene mutation represents a prognostic factor and may represent an effective therapeutic target.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  O melanoma é responsável por 4% de todos os tumores malignos da pele, mas é responsável por 80% das mortes por câncer neste site. O surgimento de terapias direcionadas contra a mutação BRAF alterou o prognóstico, daí a importância da identificação dessa mutação em pacientes com diagnóstico histológico de melanoma maligno, já que a taxa de mutações do oncogene BRAF é alta.  Objetivo:  descrever as implicações diagnósticas, terapêuticas e prognósticas da determinação da mutação do gene BRAF V600E no melanoma maligno cutâneo.  Método:  Revisão de literatura via PUBMED com a introdução dos seguintes termos de pesquisa: melanoma, melanoma e genética, melanoma e mutação BRAF, melanoma e BRAF V600E e prognóstico. 72 publicações foram identificadas.  Resultados:  Estudos múltiplos confirmaram a alta frequência do oncogene BRAF V600E mutante no melanoma cutâneo, oferecendo a possibilidade de que através da identificação de tal alteração pode ajudar a melhorar o diagnóstico e para assegurar um tratamento dirigido especificamente contra a actividade de BRAF.  Conclusões:  A identificação da mutação oncogênica BRAF representa um fator prognóstico e pode representar um alvo terapêutico eficaz.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[melanoma]]></kwd>
<kwd lng="es"><![CDATA[mutación]]></kwd>
<kwd lng="es"><![CDATA[gen]]></kwd>
<kwd lng="es"><![CDATA[BRAF V600E]]></kwd>
<kwd lng="en"><![CDATA[melanoma]]></kwd>
<kwd lng="en"><![CDATA[mutation]]></kwd>
<kwd lng="en"><![CDATA[gene]]></kwd>
<kwd lng="en"><![CDATA[BRAF V600E]]></kwd>
<kwd lng="pt"><![CDATA[melanoma]]></kwd>
<kwd lng="pt"><![CDATA[mutação]]></kwd>
<kwd lng="pt"><![CDATA[gene]]></kwd>
<kwd lng="pt"><![CDATA[BRAF V600E]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camacho Limas]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Gerson Cwilich]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Góngora Jurado]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Villalobos Prieto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco Vázquez]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[López Riverol]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualidades para el tratamiento del melanoma metastásico]]></article-title>
<source><![CDATA[An Med (Mex)]]></source>
<year>2017</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>196-207</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer statistics, 2014]]></article-title>
<source><![CDATA[Cancer J Clin]]></source>
<year>2014</year>
<volume>64</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-29</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lavanderos]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jeria]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Concha]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualizaciones en melanoma maligno cutáneo]]></article-title>
<source><![CDATA[Cuad Cir]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>47-56</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Telich Tarriba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Monter Plata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Baldín]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Apellaniz Campo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnóstico y tratamientode los tumores malignos de piel]]></article-title>
<source><![CDATA[Acta Méd Grupo Ángeles]]></source>
<year>2017</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>754-160</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eggermont]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Spatz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Robert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cutaneous melanoma]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>383</volume>
<numero>9919</numero>
<issue>9919</issue>
<page-range>816-27</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bastian]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The molecular pathology of melanoma: an integrated taxonomyof melanocytic neoplasia]]></article-title>
<source><![CDATA[Ann Rev Pathol]]></source>
<year>2014</year>
<volume>9</volume>
<page-range>239-71</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bignell]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stephens]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Edkins]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Clegg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Teague]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mutations of the BRAF gene in human cancer]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2002</year>
<volume>417</volume>
<numero>6892</numero>
<issue>6892</issue>
<page-range>949-54</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flaherty]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Puzanov]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Ribas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[McArthur]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Sosman]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibition of mutated, activated BRAF in metastatic melanoma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>363</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>809-19</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ascierto PA]]></surname>
<given-names><![CDATA[Kirkwood]]></given-names>
</name>
<name>
<surname><![CDATA[Grob JJ]]></surname>
<given-names><![CDATA[Simeone E]]></given-names>
</name>
<name>
<surname><![CDATA[Grinaldi AM]]></surname>
<given-names><![CDATA[Maio M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of V600 mutation in melanoma]]></article-title>
<source><![CDATA[J transl Med]]></source>
<year>2012</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Curtin]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fridlyand]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kageshita]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Busam]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kutzner]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distinct sets of genetic alterationsin melanoma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2005</year>
<volume>353</volume>
<page-range>2135-47</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Edmiston]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Millikan]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Groben]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Hao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma]]></article-title>
<source><![CDATA[Cancer Epidemiol Biom Prev]]></source>
<year>2007</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>992-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
<name>
<surname><![CDATA[Menzies]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Nagrial]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Haydu]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2011</year>
<volume>29</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1239-46</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Hauschild]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Robert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Haanen]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Ascierto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Larkin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved survival with vemurafenibin melanoma with BRAF V600E mutation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>2507-16</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lemech]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Infante]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arkenau]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Potential for BRAF V600 Inhibitors in Advanced Cutaneous Melanoma: Rationale and Latest Evidence]]></article-title>
<source><![CDATA[Ther Adv Med Oncol]]></source>
<year>2012</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>61-73</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lutz]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Leguisamo]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Cabral]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Gloria]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Reiter]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Agnes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imbalance in DNA repair machinery is associated with BRAFV600E mutation and tumor aggressiveness in papillary thyroid carcinoma]]></article-title>
<source><![CDATA[Mol Cell Endocrinol]]></source>
<year>2018</year>
<volume>472</volume>
<page-range>140-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez Ayala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Expósito Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bilbao González]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mínguez Gabiña]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez Rodríguez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rodeño Ortiz de Zarate]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mutación del gen BRAF V600E en el cáncer papilar de tiroides y su efecto en la terapia con yodo radiactivo (131I) posquirúrgica: ¿deberíamos modificar nuestra estrategia terapéutica?]]></article-title>
<source><![CDATA[Cir Esp]]></source>
<year>2018</year>
<volume>96</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>247-314</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oikonomou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Makrodouli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Evangelidou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Joyce]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Probert]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pintzas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[BRAFV600E efficient transformation and induction of microsatellite instability versus KRASG12V induction of senescence markers in human colon cáncer cells]]></article-title>
<source><![CDATA[Neoplasia]]></source>
<year>2009</year>
<volume>11</volume>
<page-range>1116-31</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vakiani]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Solit]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[KRAS and BRAF: drug targets and predictive biomarkers]]></article-title>
<source><![CDATA[J Pathol]]></source>
<year>2011</year>
<volume>223</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>219-29</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grover]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chana]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Richman]]></surname>
<given-names><![CDATA[PI]]></given-names>
</name>
<name>
<surname><![CDATA[Sanders]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An analysis of p16 protein expression in sporadic malignant melanoma]]></article-title>
<source><![CDATA[Melanoma Res]]></source>
<year>1998</year>
<volume>8</volume>
<page-range>267-72</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Loganzo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Shea]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Glendening]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Loss of expression of the p16/cyclin dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stages of tumor progression]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>1995</year>
<volume>55</volume>
<page-range>2713-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Meyerhardt]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[McCleary]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hollis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2012</year>
<volume>1</volume>
<page-range>890-900</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bringas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Incidencia de la mutación del gen braf en pacientes con melanoma. Estudio bicéntrico en la ciudad de Córdoba. Argentina.]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Argentina ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Católica de Córdoba]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Goto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Murata]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sakaizawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Uchiyama K Saida]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polyclonality of BRAF mutations in acquired melanocytic nevi]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2009</year>
<volume>101</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1423-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazzei]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Hochmann]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Manrique]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mariño]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Asuaga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinación de la mutación BRAF V600E en melanomas de pacientes uruguayos]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2013</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>97-102</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yépez Crow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Correlación entre mutaciones en el exón 15 del oncogén BRAF con distintas características histopatológicas y la evolución clínica de pacientes con melanoma cutáneo en diferentes estadios.]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Argentina ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Buenos Aires]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Godoy Gijón]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Estudio de la mutación BRAF V600 en el melanoma cutáneo primario y metastásico. Correlación con variables clínicopatológicas.]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Salamanca ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Salamanca]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villanueva Álvarez-Santullan]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<source><![CDATA[Determinación de las mutaciones BRAF en melanomas primarios y Metastásicos.]]></source>
<year>2017</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Complutense de Madrid]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
